Action 22
Committed by:
Support the early adoption of priority formulations and diagnostics and take steps to facilitate their wider roll-out, including by developing introductory guidance, materials, and other tools for health facilities.
Implementing Partners, and Faith-Based Organizations
Sub-Actions & Milestones
Milestone 22.2.3

Develop and distribute introductory guidance, materials, and other tools for RAL in 2018

-

PEPFAR is working with Merck and other partners on a plan for assisted introduction of RAL granules for newborns. The plan is to start with introduction in one country and, in the context of that introduction, develop educational and training materials that will be used for supporting implementation of RAL granule use for newborn in other countries where birth testing is being implemented.

-

Sub-action 22.2

Take steps to facilitate their wider roll-out, including by developing introductory guidance, materials, and other tools for health facilities.

Implementing Partners and FBO's

EGPAF and CHAI are beginning preparations for introduction of DTG and RAL (EGPAF), including production of a DTG introduction toolkit. DNDi is working with in-country partners on expand uptake of LPV/r solid formulations for the roll-out of introductory materials 

-

Milestone 22.2.1

Develop and distribute introductory guidance, materials, and other tools for DTG in 2018

-

-

Milestone ongoing

Milestone 22.2.2

Develop and distribute introductory guidance, materials, and other tools for 4-in-1 granules in 2018

-

-

-

Sub-action 22.1

Support the early adoption of priority formulations and diagnostics

Implementing Partners and FBO's

GAP-f partners have been discussing with ViiV and regulatory authorities to determine the best regulatory pathways for pediatric DTG (10 mg scored and 50 mg scored tablets) and ways to accelerate registration and introduction of DTG and RAL at country level.

-

Milestone 22.1.1

Work with ViiV on registration of DTG for children

CHAI

In November, CHAI issued in collaboration with ViiV an RFP for development of generic pediatric formulations of DTG, with the announcement of manufacturers selected expected in February.

-

Document (s)

-

-

-

-

Updates

Notes

Responsible